| Grant number: | 25/10861-0 |
| Support Opportunities: | Research Grants - Young Investigators Grants |
| Start date: | July 01, 2026 |
| End date: | June 30, 2031 |
| Field of knowledge: | Biological Sciences - Pharmacology - General Pharmacology |
| Principal Investigator: | Guilherme Henrique Souza Bomfim |
| Grantee: | Guilherme Henrique Souza Bomfim |
| Host Institution: | Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
| City of the host institution: | São Paulo |
| Associated researchers: | Vagner Roberto Antunes |
| Associated scholarship(s): | 26/20149-9 - Therapeutic Targeting of NCKX4-Driven Calcium Dysregulation in Vascular Aging, Stroke, and Cognitive Impairment, BP.JP |
Abstract
Aging is the primary nonmodifiable risk factor for cardiovascular diseases (CVDs) and significantly increases the risk of cerebral small vessel diseases (SVDs), stroke, and neurodegenerative disorders. Aortic stiffening and neurovascular remodeling are key contributors to hypertension, cognitive impairment, and dementia in older adults. At the cellular level, dysfunctional calcium (Ca2+) handling in vascular smooth muscle cells (VSMCs) leads to increased arterial stiffness and microvascular damage. However, the molecular mechanisms linking vascular aging and neurovascular dysfunction remain poorly defined. This proposal identifies the (Na+)-sodium/Ca2+-calcium (K+)-potassium-dependent exchanger 4, (NCKX4), a Ca²¿-related protein encoded by SLC24A4, as a key regulator of cytosolic Ca2+ clearance in both systemic and neurovascular tissues. NCKX4 removes large amounts of intracellular Ca2+ within milliseconds and may play a pivotal role in maintaining vascular tone and neurovascular integrity. Its function in VSMCs, aortic remodeling, and neurocognitive aging remains unexplored. Notably, NCKX4 is recognized by Brazilian and international health institutes as a gene associated with physiopathological processes. We hypothesize that the decline of NCKX4 with age leads to impaired Ca2+ clearance, vascular remodeling, increased stroke risk, and cognitive dysfunction. Preliminary data from this project show a sex- and age-related reduction in NCKX4 expression and function in large vessels, associated with early arterial stiffening. NCKX4 is also highly expressed and decline with the age in hippocampal neurons involved in memory and learning. Its dysfunction may represent a common molecular link between cardiovascular and neurodegenerative diseases. The central goal of this proposal is to establish NCKX4-mediated Ca2+ clearance as a therapeutic target for age- and sex-dependent aortic remodeling, ischemic stroke, and neurovascular damage. We propose that NCKX4 loss contributes to impaired neurovascular coupling, vascular degeneration, and cognitive decline. The research is structured into three specific aims:Aim 1: Determine the impact of NCKX4 age-related decline on cardiovascular performance, VSMCs stiffness, and arterial remodeling using in vivo and in vitro approaches.Aim 2: Define the consequences of NCKX4 loss on stroke susceptibility, neurovascular integrity, and cognitive function through histological, imaging, electrophysiological, and behavioral analyses.Aim 3: Develop therapeutic strategies to restore, preserve, or rescue NCKX4 function using lifestyle interventions, ANVISA-approved small molecules (identified here by structure-based docking) and gene therapy via AAV-mediated NCKX4 delivery with miR-712* inhibition.This innovative research uncovers a novel role for NCKX4 in systemic and neurovascular aging. It is the first to mechanistically link aortic remodeling with CVDs, SVDs, and hippocampal dysfunction.Conceptual Innovations: 1) Identify NCKX4 as a regulator of Ca²¿ dynamics in the aorta and hippocampus, linking its age- and sex-related decline to vascular and neurovascular dysfunction. 2) Establish aortic remodeling as an upstream trigger of cerebral SVDs, integrating macro- and microvascular changes across structural and functional domains. 3) Address sex as a biological variable in vascular-brain aging, highlighting NCKX4 as a shared regulator of VSMCs and neurons.Technical/Translational Innovations: 1) Assess whether exercise training can reverse or mitigate phenotypes linked to NCKX4 deficiency. 2) Validate ANVISA-approved drugs identified by docking to modulate NCKX4 activity, supporting pharmacological repurposing. 3) Use human VSMCs and Alzheimer's disease models to confirm clinical relevance, and develop a novel gene therapy platform based on AAV-NCKX4 co-delivery with miR-712* inhibition. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |